Edition:
United Kingdom

Syndax Pharmaceuticals Inc (SNDX.OQ)

SNDX.OQ on NASDAQ Stock Exchange Global Select Market

9.27USD
8:59pm GMT
Change (% chg)

$-0.21 (-2.22%)
Prev Close
$9.48
Open
$9.42
Day's High
$9.82
Day's Low
$9.23
Volume
57,711
Avg. Vol
75,245
52-wk High
$15.65
52-wk Low
$7.43

Select another date:

Thu, Feb 1 2018

BRIEF-Syndax Announces Immuno-Oncology Clinical Trial Collaboration With Astrazeneca

* SYNDAX ANNOUNCES IMMUNO-ONCOLOGY CLINICAL TRIAL COLLABORATION WITH ASTRAZENECA

BRIEF-Syndax Pharmaceuticals Announces Clinical Collaboration To Evaluate Entinostat In Combination With Anti-Pd-L1 Cancer Immunotherapy In Breast Cancer

* SYNDAX PHARMACEUTICALS ANNOUNCES CLINICAL COLLABORATION TO EVALUATE ENTINOSTAT IN COMBINATION WITH ANTI-PD-L1 CANCER IMMUNOTHERAPY IN BREAST CANCER

BRIEF-Syndax Pharmaceuticals reports Q3 loss per share $0.68

* Syndax pharmaceuticals reports third quarter 2017 financial results and provides clinical and business update

BRIEF-Syndax announces $25 million registered direct offering of common stock

* Syndax announces $25 million registered direct offering of common stock

BRIEF-Syndax Pharma enters into license agreement with unit of Allergan

* On Oct 13, co entered into license agreement with Vitae Pharmaceuticals, a subsidiary of Allergan Plc​ - SEC filing

BRIEF-‍Syndax announces dosing of first patient in trial of Entinostat for treatment of recurrent breast cancer

* ‍Syndax announces dosing of first patient in pivotal trial of entinostat for treatment of advanced or recurrent breast cancer in Japan by partner kyowa hakko kirin​

Select another date: